Alk-abello A/s Class B · OMXCOP:ALK_B
Alk-abello A/s Class B — Alk-Abello As B Shs New — Q4 2024 Earnings Presentation
12 slides from Alk-abello A/s Class B's earnings presentation, Feb 19, 2025
Slide 1: Q4 2024 presentation
Q4 2024 presentation Webcast 19 February 2025
Slide 2: Agenda and presenters
2 Webcast 19 February 2025 Agenda and presenters • Q4 highlights • Full-year highlights • Performance o Market trends o Product sales trends o Financials President & CEO EVP, Group CFO VP, Head of IR • Strategy Peter Halling Claus Steensen Sølje Per Plotnikof o 2024 achievements o 2025 ambition This
Slide 3: Q4 highlights
3 Webcast 19 February 2025 Q4 highlights Results in line with full-year outlook from November 14 • Strong performance in Europe; EU tablet sales grew by 32% • Capacity costs increased on investments in growth initiatives, one-off costs related to in-licencing activities and DKK 26 million in optimis
Slide 4: FY: Financial and strategic progress
4 Webcast 19 February 2025 FY: Financial and strategic progress ALK delivered on short-term targets and launched new strategy • 15% revenue growth, driven by EU tablet sales • EBIT up 65% (l.c.) on sales growth, margin expansion and efficiencies • Expansion of addressable markets in respiratory alle
Slide 5: ALK markets
5 Webcast 19 February 2025 ALK markets European markets key contributor to growth Europe North America International markets 71% 16% 13% Double-digit growth across key Double-digit growth in tablets; sales Growth in tablet revenue; decrease in markets, driven by all product lines of legacy products
Slide 6: ALK portfolio
6 Webcast 19 February 2025 ALK portfolio Tablet and Jext® sales grew by double-digits Tablets SCIT/SLIT-drops Other products 52% 37% 11% Growth in all regions; EU sales up 31% Growth driven by Europe on higher Jext® sales recovered; PRE-PEN®, on patient inflow and improved pricing volumes, price and
Slide 7: Sales growth drives margin improvements in 2024
7 Webcast 19 February 2025 Sales growth drives margin improvements in 2024 Costs include DKK 75 million one-offs to optimisations DKK million 2024 2023 Change Gross profit DKKm Revenue 5,537 +15% 4.000 70% 4,824 3.000 65% Gross profit 3,552 3,035 2.000 60% 1.000 Gross margin 64.2% 62.9% 0 55% 2020 2
Slide 8: Key strategic achievements
8 Webcast 19 February 2025 Key strategic achievements 2024 • Allergy+: Implementation progresses well and is delivering results Innovate • ~2.6 million patients treated; 200k more than last year We will 2028 innovate to create a • Respiratory allergy: Strong momentum for tablets balanced pipeline •
Slide 9: Key strategic must-wins
9 Webcast 19 February 2025 Key strategic must-wins 2025 • Keep momentum and grow Help more people with allergy • Maximise value of tablet portfolio Secure paediatric approvals for tablets in Europe/North America Successfully launch tablets for children across markets Encouraging feedback from first
Slide 10: 2025 outlook
10 Webcast 19 February 2025 2025 outlook Robust revenue and earnings growth in line with long-term financial ambitions Revenue Key assumptions • Volume-driven growth across regions and product lines DKKm Revenue Growth in l.c. 9-13% • Double-digit growth in tablet sales; reduced impact from 7.000 6.
Slide 11: Q&A session
Q&A session
Slide 12: Upcoming news-flow
12 Webcast 19 February 2025 Upcoming news-flow Next 12 months Market Planned event Respiratory allergy Europe Launches of ACARIZAX® for children China Initiation of bridging trial with ACARIZAX® India Launch of ACARIZAX® USA Approval of ODACTRA® for children use and subsequent launch Canada Approval
Alk-Abello As B Shs New — Q4 2024 Earnings Presentation on 6ix